AA
URGN icon

ALPS Advisors’s UroGen Pharma URGN Stock Holding History

ALPS Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,839
Closed -$340K – 1160
2025
Q2 		$340K Sell
24,839
-7,923
-24% -$76K ﹤0.01% 889
2025
Q1 		$362K Sell
32,762
-1,359
-4% -$14.5K ﹤0.01% 715
2024
Q4 		$363K Sell
34,121
-28
-0.1% -$335 ﹤0.01% 758
2024
Q3 		$434K Buy
+34,149
New +$507K ﹤0.01% 629
2020
Q2 		– Sell
-38,139
Closed -$680K – 831
2020
Q1 		$680K Sell
38,139
-4,451
-10% -$120K 0.01% 376
2019
Q4 		$1.42M Buy
42,590
+871
+2% +$23.8K 0.01% 269
2019
Q3 		$994K Sell
41,719
-1,740
-4% -$56.9K 0.01% 313
2019
Q2 		$1.56M Sell
43,459
-4,271
-9% -$157K 0.01% 260
2019
Q1 		$1.76M Buy
47,730
+10,520
+28% +$441K 0.01% 241
2018
Q4 		$1.6M Buy
37,210
+9,156
+33% +$412K 0.01% 243
2018
Q3 		$1.32M Buy
28,054
+5,603
+25% +$260K 0.01% 311
2018
Q2 		$1.12M Buy
22,451
+2,045
+10% +$119K 0.01% 315
2018
Q1 		$1.01M Buy
20,406
+5,803
+40% +$291K 0.01% 312
2017
Q4 		$543K Buy
14,603
+2,813
+24% +$100K ﹤0.01% 474
2017
Q3 		$372K Buy
11,790
+984
+9% +$21.7K ﹤0.01% 708
2017
Q2 		$195K Buy
+10,806
New +$188K ﹤0.01% 754

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

ALPS Advisors's URGN Position: Q3 2025 in Review

ALPS Advisors sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 24,839 shares — an estimated $340K sold.

ALPS Advisors first reported a position in URGN in Q2 2017 and held it in 16 quarters. The position peaked at $1.76M in Q1 2019. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • ALPS Advisors reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • ALPS Advisors sold 24,839 UroGen Pharma shares in Q3 2025, an estimated $340K.
  • ALPS Advisors first reported a position in UroGen Pharma in Q2 2017 and held it in 16 quarters.
  • ALPS Advisors's UroGen Pharma position peaked at $1.76M in Q1 2019.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on ALPS Advisors's 13F filing for Q3 2025, filed 5 Nov 2025.